Back

The effects of SGLT-2 inhibitors vs renin-angiotensin-aldosterone system inhibition on cardiovascular outcomes of heart failure with preserved ejection fraction: network meta-analysis

21 May 2022 (08:30 - 18:50)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Chronic Heart Failure 1 Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Jesus Hernando Diaz Acevedo

hamil, Dalton (United States of America)

38 More presentations in this session

Presentation thumbnail
Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial
Professor M. Boehm (Homburg, DE)
Abstract Slides
Presentation thumbnail
Novel kidney injury markers (NGAL and KIM-1) and outcomes in patients with heart failure- Systematic review and meta-analysis
Doctor A. Kumar (Little Rock, US)
Abstract Slides
Presentation thumbnail
Right ventricular dilatation as a manifestation of right ventricular dysfunction in patients with HFrEF: a new concept of evaluation
Doctor J. Benes (Prague, CZ)
Abstract Slides
Presentation thumbnail
Combination treatment by epoxyeicosatrienoic acid analog and angiotensin-convertase enzyme inhibitor in congestive heart failure: a preclinical study on animal model
Doctor P. Kala (Prague, CZ)
Abstract Slides
Presentation thumbnail
Long-term prognostic implications of in-hospital changes in N-terminal pro-B-type natriuretic peptide levels among hospitalized patients with atrial fibrillation with or without heart failure
Mr A. Samaras (Thessaloniki, GR)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Chronic Heart Failure 1

The Event

Event poster

Heart Failure 2022

21 May 2022 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources